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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a vascular multi-organ system disorder. Its diagnostic
criteria include epistaxis, telangiectases in mucocutaneous sites, arteriovenous malformations (AVMs), and familial
inheritance. HHT is transmitted as an autosomal dominant condition, caused in 85% of cases by mutations in either
Endoglin (ENG) or Activin receptor-like kinase (ACVRL1/ACVRL1/ALK1) genes. Pathogenic mutations have been
described in exons, splice junctions and, in a few cases with ENG mutations, in the proximal promoter, which
creates a new ATG start site. However, no mutations affecting transcription regulation have been described to date
in HHT, and this type of mutation is rarely identified in the literature on rare diseases.
Methods: Sequencing data from a family with HHT lead to single nucleotide change, c.-58G > A. The functionality
and pathogenicity of this change was analyzed by in vitro mutagenesis, quantitative PCR and Gel shift assay.
Student t test was used for statistical significance.
Results: A single nucleotide change, c.-58G > A, in the proximal ENG promoter co-segregated with HHT clinical
features in an HHT family. This mutation was present in the proband and in 2 other symptomatic members,
whereas 2 asymptomatic relatives did not harbor the mutation. Analysis of RNA from activated monocytes from the
probands and the healthy brother revealed reduced ENG mRNA expression in the HHT patient (p = 0.005). Site-
directed mutagenesis of the ENG promoter resulted in a three-fold decrease in luciferase activity of the mutant c.-
58A allele compared to wild type (p = 0.005). Finally, gel shift assay identified a DNA-protein specific complex.
Conclusions: The novel ENG c.-58G > A substitution in the ENG promoter co-segregates with HHT symptoms in a
family and appears to affect the transcriptional regulation of the gene, resulting in reduced ENG expression. ENG c.-
58G > A may therefore be a pathogenic HHT mutation leading to haploinsufficiency of Endoglin and HHT
symptoms. To the best of our knowledge, this is the first report of a pathogenic mutation in HHT involving the
binding site for a transcription factor in the promoter of ENG.
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Background
Hereditary hemorrhagic telangiectasia (HHT), also
known as Rendu-Osler-Weber syndrome [1, 2], is a
vascular disorder with autosomal dominant inherit-
ance. The latest epidemiological data reveal that HHT
affects approximately 1 in every 5,000 individuals [2].
The clinical symptoms, known as the Curaçao criteria
[3], diagnose an HHT patient when at least 3 of the 4
criteria are present: epistaxis (nose bleeds), mucocuta-
neous telangiectases, arteriovenous malformations
(AVMs) affecting mostly the lung, liver and brain, and
an autosomal dominant pattern of familial inheritance.
Hereditary Hemorrhagic Telangiectasia is caused by
mutations in at least one of the 3 genes involved in
the transforming growth factor-beta (TGF-β) signaling
pathway [4]. Endoglin (ENG, chromosome 9q34), Acti-
vin A receptor type II-like 1 (ACVRL1/ACVRL1/ALK1,
chromosome 12q13), and MADH4/SMAD4 (chromo-
some 18q21) mutations cause HHT1 (OMIM 187300),
HHT2 (OMIM 600376), and the combined Juvenile
Polyposis/HHT (JP/HHT) syndrome (OMIM 175050),
respectively [5–7]. There are two further unidentified
genes that can cause HHT: HHT 3 between 141.9 and
146.4 Mb on chromosome 5q and HHT4 on chromo-
some 7p between D7S2252 and D7S510.130 [8, 9]. Re-
cently, BMP9 mutations have been shown to give rise
to HHT5, although the contribution of BMP9 muta-
tions to HHT is estimated to be very low (<1%) [10].
The genes that are mutated in HHT encode proteins
that mediate signaling by the TGF-β superfamily. In the
TGF-β signaling cascade, the type II receptor coopera-
tively recruits and transphosphorylates the type I recep-
tor by direct contact with TβRI [11]. In endothelial cells,
upon ligand binding, TβRII can associate with two dif-
ferent TGF-β type I receptors: ALK-5 or ALK-1 [12].
Endoglin is an auxiliary receptor that modulates both
complexes in opposite manners. Thus, whereas Endoglin
promotes signaling through ALK-1, it inhibits the ALK-5
pathway [13]. In turn, ALK-1 and ALK-5 activate distinct
R-Smad pathways, resulting in opposing endothelial cell
responses in proliferation, migration, and pro- or anti-
angiogenic gene expression.
More than 600 different mutations have been identi-
fied in ENG and ACVRL1 in HHT families (HHT muta-
tion database; http://www.arup.utah.edu/database/hht/).
These mutations range from single base-pair changes
to large deletions of multiple exons and are of all types,
including substitutions, duplications, and deletions.
There are no common mutation “hotspots” in either
gene, and mutations have been observed across all cod-
ing regions.
Considering substitutions, missense mutations are the
most common type observed in ENG and ACVRL1, and
mutations have been identified in all exons of both
genes, including exon/intron boundaries and splice-site
junctions. However, the proportion of mutations causing
a frameshift or stop codon in the protein (i.e., indels and
non-sense mutations) are more frequent in ENG than in
ACVRL1 [14–16].
Although many ENG mutations have been identified
in the extracellular region of the protein, which is the
largest part of the protein, very few mutations have been
identified in the transmembrane and cytoplasmic do-
mains [16]. Large deletions or duplications of one or
more exons account for 6–10% of all ENG and ACVRL1
mutations [17]. Large deletions in the Endoglin gene,
encompassing promoter and several exons or the whole
gene, have previously been described by our group [18].
Mutations in the 5′UTR region of ENG (c.-9G > A and
c.-127C > T) have also been found to cause HHT. They
were determined to be pathogenic by creating an alter-
native, out-of-frame transcription start codon, but the
possibility of altering binding sites for transcriptional
factors could not be discarded. Interestingly, (c.-9G > A)
is a hypomorphic variant that can be detected in a
homozygous state.
These mutations emphasize the need for including
the ENG 5′UTR region in routine molecular diagnos-
tic testing for HHT [19]. However, to date, few muta-
tions affecting a site in the promoter of either
Endoglin or ACVRL1/ALK1 have been reported. A
mutation in the regulatory site present in intron 6
(c.772 + 27G > C) of ACVRL1 has been described in
an HHT2 Chinese family [20].
Although the 5′-flanking region of the Endoglin gene
lacks consensus TATA and CAAT boxes, it contains
GC-rich regions and consensus motifs for Sp1, ets,
GATA, and TGF-β (Smads), and estrogen-responsive
elements. The upstream −400/+341 region is able to
display tissue-specific activity in human endothelial
cells. Analysis of various deletion constructs demon-
strated the existence of a basal promoter region within
the −81/+350 fragment [21].
In the present study, we describe, for the first time, a
pathogenic mutation that causes HHT type 1 by affect-
ing a single base pair nucleotide change at the c.-58G >
A position of the proximal promoter of Endoglin, which
is embedded in this basal promoter region.
Methods
Patient samples
Blood samples were collected at different hospitals
and sent to our institute. They were received on the
day after blood extraction. Informed consent was ob-
tained from each patient. HHT diagnosis was based
on the clinical Curaçao criteria [3]. Each sample was
anonymously treated and identified with a code
number.
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Ethics statement request
The human blood samples and clinical data reported in this
manuscript were obtained with prior approval from the ap-
propriate ethics committees of the CSIC for the research
conducted in the Centro de Investigaciones Biológicas
(CIB, Madrid), the CEIC (Clinical Research Ethics Commit-
tee) of the Cantabrian Health Service for patients at the
Hospital of Sierrallana (Torrelavega, Santander, Cantabria),
and the Medical Genetics department of the Hospital
Valdecilla (Santander, Cantabria). Research was carried out
in compliance with the Helsinki Declaration (http://
www.wma.net/en/30publications/10policies/b3/index.html),
keeping the results strictly confidential, with numerical
codes for patient identification. http://www.wma.net/en/
30publications/10policies/b3/index.html.
DNA extraction and mutation analysis
Genomic DNA was extracted from peripheral blood,
using the QIAamp kit (Qiagen, Gmbh, Germany). The
coding exons from Endoglin, the 9 translated exons from
ACVRLK1/ALK1, including exon 1 (transcribed but not
translated), the exon intron boundaries (50 bp), and the
proximal promoters of both genes were amplified by
PCR and then sequenced using specific primers. MLPA
was also performed for both genes to detect any changes
in copy number. The primer sequences and PCR condi-
tions have already been reported [4, 14]. PCR products,
which were excised and cleaned from the gel (Millipore,
Germany), were sequenced in forward and reverse orien-
tation on an Applied Biosystems sequencer using the
dye terminator sequencing kit according to the manufac-
turer’s instructions. Sequences were compared with the
following references for ACVRL1/ALK1: OMIM 601284
Gene ID: 94; Genomic ID: NG_009549.1; c-DNA ID:
NM_000020.2; and Protein ID: NP_000011. For ENG,
the references were OMIM 131195 Gene ID: 2022; Gen-
omic ID: NG_009551.1; c-DNA ID: NM_001114753.1;
and Protein ID: NP_001108225.12. The following data-
base was used for HHT: http://arup.utah.edu/database/
HHT/. Next, if no changes were found in the DNA se-
quence comparisons, MLPA [22] was performed accord-
ing to the manufacturer’s instructions using the P093
Salsa MLPA HHT/PPH1 probe set (MRC-Holland,
Amsterdam, The Netherlands). DNA sequences and
MLPA analyses were performed by Secugen S.L (Madrid,
Spain). In the index case analyzed in this manuscript,
only a change G > A, in position −58 bp of Endoglin pro-
moter was observed; it was considered a variation of the
gene and had an unknown effect (VUS).
Site-directed mutagenesis
Site-directed mutagenesis was carried out from a con-
struct encompassing 350 bp upstream of the transcrip-
tion initiation start of ENG, including a 150-bp
transcribed untranslated region before the codon start
with the luciferase reporter gene in the pXP2 vector
(−350/+150 ENG pXP2). Mutagenesis was performed
using the Quick Change Site-Directed Mutagenesis kit
from Agilent Technologies, according to the manufac-
turer’s instructions. These procedures were followed by
DpnI digestion to eliminate the original wild type DNA
template. Oligonucleotides used for the mutagenesis
were: ENG -58Mut:
Fwd: 5′- CCACAGCCCTGCCACTGGACA-3′
Rev: 5′-TGTCCAGTGGCAGGGCTGTGG-3′
Cell culture
Human microvasculature endothelial cells, HMEC-1,
were grown on 0.2% gelatin (Sigma-Aldrich) in PBS-
coated plates in MCDB-131 medium (Gibco) supple-
mented with 10% FCS (Gibco), 1 ng/ml of EGF and
1 μg/ml of hydrocortisone (Sigma), 2 mM L-glutamine
(Gibco) and 100 U/ml of penicillin and streptomycin
(Gibco).
Transfections and luciferase assays
Superfect® Transfection Reagent (Qiagen), was used for
transient transfection according to the manufacturer’s
instructions. A total of 1 μg from Luciferase Plasmid Re-
porters DNA [either wild type or mutated (−350/+150
ENG pXP2)] and 20 ng of pSV40-βgal reporter plasmid
(for transfection normalization) were incubated in Opti-
MEM (Gibco) with Superfect for 15 min at room
temperature. The DNA-transfection reagent complexes
were added to cells that were 80% confluent in P-24
wells. Transfection was allowed to proceed for 24 h at
37 °C and 5% CO2.
Cells were lysed in 1× lysis buffer from Promega. Rela-
tive units of luciferase (Promega luciferase reagent) were
measured in a Glomax luminometer (Promega), and β-
galactosidase units as measured by Galacto-light (Tro-
pix) were used to normalize transfection efficiency. Each
condition was repeated in triplicate. Treatments with
TGF-β1 (Preprotech) proceeded for 24 h with 10 ng/ml.
The control reporters of TGF-β, CAGA-luc, and BRE-
luc were used in parallel as reporter controls of the
TGF-β response.
RNA gene expression
Isolation of MNCs, culture and RNA extraction
From 5 ml samples of peripheral blood from patients,
the total fraction of MNCs (mononuclear cells) was iso-
lated in a Ficoll gradient (Lymphocyte Separation
Medium, Lonza). The MNC fraction was plated and cul-
tured for 24 h in DMEM medium containing 10% fetal
bovine serum (FBS, Gibco). Total RNA from these acti-
vated MNCs was isolated using the NucleoSpin RNA
purification kit from Macherey-Nagel (GmbH&Co).
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Quantitative RT-PCR
For quantitative analysis of ACVRL1/ALK1 and ENG
transcripts, total RNA was reverse-transcribed using the
Reverse Transcriptase AMV cDNA Synthesis kit
(Roche). The resulting cDNA was used as a template for
real-time PCR performed using the SYBR Green PCR
system (BioRad), with the following primers. ACVRL1/
ALK1: Fwd 5′-ATCTGAGCAGGGCGACAGC-3′ and
Rev 5′-ACTCCCTGTGGTGCAGTCA-3′; ENG Fwd 5′-
GCCCCGAGAGGTGCTTCT-3′ and Rev 5′-TGCAG-
GAAGACACTGCTGTTTAC-3′. As an internal control,
mRNA levels of 18S were measured using these primers:
Fwd 5′-CTCAACACGGGAAACCTCAC-3′ and Rev 5′-
CGCTCCACCAACTAAGAACG-3′. Amplicons were
detected using an iQ5 system (BioRad). Each experiment
was performed in triplicates.
Gel shift assay (EMSA) of proximal ENG mobility
Nuclear extracts from confluent HMEC-1 cultures were
obtained using a Nuclear Extract kit (Active Motif ). The
amount of protein was determined by the Bradford tech-
nique (Bio-Rad), and 10 μg of total nuclear extract was
used for incubation with the 5′ biotinylated oligonucleo-
tide probe from Sigma Aldrich. Complementary oligonu-
cleotides encompassing the −69 to −56 region of
Endoglin promoter were annealed by heating 95 °C for
3 min, slowly cooling down to RT, and then incubating
overnight at 4 °C.
The gel shift assay was carried out following the
protocol of Gelshift™ Chemiluminescent EMSA.
Briefly, 20 ng annealed probe was incubated with
10 μg nuclear extract in the presence of 2 μg of
polydI-dC as non-specific competitor. Specific compe-
tition assays occurred with an excess (100-fold) of wt
cold unlabeled annealed probe and the same amount
of mutated cold unlabeled probe. Protein-DNA bind-
ing was allowed to proceed for 30 min at 4 °C; then,
samples with loading buffer were loaded in a 6% non-
denaturing polyacrylamide gel in 0.5× TBE and elec-
trophoresed for 1 h at 4 °C and 150 V. Next, the
DNA-protein complexes and free probe were trans-
ferred to a nylon membrane by electroblotting. DNA-
protein complexes were crosslinked by UV to the
nylon membrane. The membrane was processed by
blocking and was then incubated with the
streptavidin-HRP conjugate for 30 min. After being
washed, the membrane was developed by the Super
signal chemiluminescent Kit (Thermo-Scientific), ac-
cording to the manufacturer instructions, and visual-
ized with a Molecular Imager, Chemi-Doc.
Statistics
Data were subject to statistical analysis, and the results
are shown as the mean ± SD. Differences in mean values
were analyzed using Student’s t-test. In the figures, the
statistically significant values are marked with asterisks
(*p < 0.05; **p < 0.01; and ***p < 0.005).
Results
Correlation between the presence of deletions in ENG
and clinical phenotype
DNA from a patient presenting epistaxis, gastric bleed-
ing, telangiectasia and liver arteriovenous malformations
was referred to our laboratory for genetic diagnosis after
a clinical diagnosis of HHT was presented. After sequen-
cing all exons, intron boundaries, and proximal pro-
moter regions of ACVRL1/ALK1 and ENG and the
MLPA of both genes, we could not find any mutations
in the DNA. Only a change, G > A, in position −58 bp of
Endoglin promoter was observed, and it was considered
to be a variation of the gene with an unknown effect.
To determine whether the change could be the muta-
tion causing HHT symptoms, 4 direct relatives of the
index case were sequenced. The c.-58 G > A change was
identified in two of them, and those two presented epi-
staxis and telangiectasia, whereas the other two relatives
had no apparent clinical symptoms (epistaxis or telangi-
ectasia in either adult). The phenotype-genotype correl-
ation between led us to consider that the change could
be pathogenic (Fig. 1). Clinically, the index case for
HHT (I-1) (Fig. 1) was 79 years old and suffered from
frequent epistaxis, exhibited many telangiectases on the
face and hands and had arteriovenous malformations in
the liver and gastric bleeding; therefore, it could not be
considered a “mild” phenotype. Patient II-2 (Fig. 1) was
a 45-year-old male who suffered from frequent epistaxis
and had several telangiectases on the face and mucosa.
No screening for AVMs occurred. The III-3 proband
was 19 years old and had mild epistaxis and few telangi-
ectases on the lips and fingertips.
Site-directed mutagenesis of Endoglin proximal promoter
and transfection
To assess whether an Endoglin c.-58 bp G > A change
could affect endoglin transcription, we performed site-
directed mutagenesis on an Endoglin promoter pCD105
(−450/+350) with a pXP2 luciferase reporter [23].
HMEC-1 cells were transfected with either the wild
type or mutated sequence of the endoglin promoter. To
control cell transfection, the pSV40-βgal reporter plas-
mid was also co-transfected. At the same time, HMEC-1
Biotinylated wt fwd −69/-56 5′- GGTGCCCGCCCGCAGCCCTGCCAC -3′
Biotinylated wt rev −69/-56 5′- GTGGCAGGGCTGCGGGCGGGCACC -3′
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cells were incubated in the presence or absence of
10 ng/ml of TGF-β1 for 24 h.
As shown in Fig. 2, the wild type endoglin promoter
had 3-fold more luciferase activity than did the mutated
promoter (c.-58 G > A). This difference was statistically
significant, p < 0.005. TGF-β treatment upregulated both
the wild type and mutated promoters; therefore, the mu-
tation does not seem to involve a TGF-β responsive
element.
However, there was significantly more relative upregu-
lation (p < 0.05) in the wild type than in the mutant after
TGF-β treatment.
RNA endoglin expression of HHT and wild type
monocytes activated in vitro
Monocytes do not express significant levels of Endoglin
[24]. However, the expression of Endoglin is triggered
during the process of monocyte activation and transition
to macrophage.
Because haploinsufficiency is the mechanism under-
lying HHT [2], and the (c.-58 G > A) in Endoglin pro-
moter seemed to reduce, at least in vitro, the promoter
activity in a reporter (Fig. 2), we decided to assess acti-
vated monocytes from 1 HHT patient and his healthy
brother, evaluating Endoglin expression in both patients
side by side. In the case of the Endoglin RNA from the
HHT patient, activated monocytes expressed signifi-
cantly less Endoglin and ACVRL1/ALK1 compared to
the healthy donor (p < 0.005) (Fig. 3). Figure 3 shows the
relative expression of ENG and ACVRL1/ALK1 of the af-
fected patient compared to the healthy sibling in acti-
vated monocytes. The amount of ENG RNA in the wild
Fig. 1 a Schematic representation of the family tree with the distribution of HHT and normal relatives. b Clinical diagnostic criteria of the affected
relatives. c Mutated sequence corresponding to this particular HHT family, showing the nucleotide substitution c.-58 G > A at the proximal
promoter of Endoglin. Arrows point to the two unaffected individuals, who were also sequenced
Fig. 2 Histograms representing the relative luciferase activity of wild
type and mutated Endoglin promoter reporters after transfection into
endothelial HMEC-1 cells. Site-directed mutagenesis was performed on
the wild type promoter/reporter plasmid (350/+350 CD105 pXP2) of
Endoglin. The effect of TGF-β treatment is also shown
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type sample was significantly higher than that in the mu-
tant one (Fig. 3). ACVRL1/ALK1 expression was also de-
creased, which may be explained by a crosstalk between
both genes, published before [24]. Therefore, these re-
sults represent in vivo confirmation of the deficient ex-
pression of Endoglin in the HHT patient related with
the change (c.-58 G > A) in the promoter. Next, we de-
cided to test whether the binding of a transcription fac-
tor could be prevented by changing G to A.
Changing G > A in the promoter interferes with
transcription factor binding
The MatInspector program (Genomatix) (2005) [25] pre-
dicted that the change (−58 G >A) was in a Sp1/GC factor
consensus that also overlapped also with SBE (Smad bind-
ing elements) and partially overlapped a core region for the
core promoter element for RNA pol II (CPE) transcription
for TATA-less promoters, in the case of Endoglin. The site
where the mutation was placed and the putative binding
places for these transcription factors is depicted in Fig. 4.
The next step was to synthesize a double-stranded
oligonucleotide probe covering the region encompassing
the mutation and then test whether we could detect
DNA-protein complexes in a gel shift assay. As shown
in Fig. 5, when the nuclear extract from endothelial cells
(HMEC-1 cell line) was incubated with the double-
stranded biotinylated oligonucleotide, in the presence of
unspecific competitor poli (dI-dC), a retardation band
could be detected (lane 2). However, the band was not
visualized after the sample was incubated with a 100×
excess of the unlabeled double-stranded nucleotide (cold
probe) (lane 3). When there was competition between
the mutated oligonucleotide and the wild type nucleo-
tide, the retarded band was not so efficiently decreased
(lane 4). Therefore, there was a protein complex binding
the region in which the mutation was placed, which, ac-
cording to the predictions in Fig. 4, is a complex of the
Sp1/GC-rich family of transcription factors. Therefore,
the results suggest that the mutation (c.-58 G > A) in the
proximal promoter of Endoglin precludes or disturbs
Sp1 binding to initiate transcription. This explains why
transcription is inefficient and Endoglin haploinsuffi-
ciency occurs.
Discussion
HHT is caused by mutations in the transforming growth
factor-beta (TGF-β) signaling pathway genes ENG,
ACVRL1/ALK1, and SMAD4 [5–7], and the more recently
identified BMP9 [9].
Haploinsufficiency has been postulated to be the mech-
anism of pathogenesis leading to HHT. In this particular
case, mutation (c.-58 G >A) in the promoter of Endoglin
precluded Sp1 binding and the initialization of efficient
transcription. Transcription proceeds normally only from
the wild type allele. Therefore, the mutation described out-
lines a new way to generate Endoglin haploinsufficiency.
With the advent of next generation sequencing
(NGS), a new era has begun in which HHT molecular
diagnostics can be performed more quickly, easily,
and inexpensively. McDonald and coworkers [15] have
set up multi-gene NGS panels for the rapid molecular
diagnosis of HHT.
Fig. 3 Results of RT quantitative PCR showing the RNA transcription
levels of Endoglin and ACVRL1/ALK1 genes of activated monocytes
from a HHT patient compared with his control brother. The results
are compared to the endogenous control 18S. The qPCR was
repeated three times, and the results shown are representative, with
triplicates for each sample
Fig. 4 Schematic representation of the proximal promoter region encompassing the −58 (G > A) site and the transcription factors binding to it,
according to the MatInspector program (Genomatix)
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However, approximately 5-10% of individuals clinically
identified as having HHT, according to the clinical Cura-
çao criteria, currently have no known genetic cause [15].
Should we look for additional causative genes or genetic
modifiers beyond those already described? Alternatively,
are deep intronic variants or changes in the regulatory
(promoter, enhancer) regions of the already known ENG,
ACVRL1/ALK1, MADH4, and BMP9 genes responsible
for HHT, which accounts for the percentage of genetic-
ally undiagnosed patients?
Current clinical testing protocols, including whole ex-
ome sequencing (WES), only involve exons and intronic
boundaries. To cover regulatory and deep intronic re-
gions, the advent of targeted whole gene capture of the
relevant loci, including introns and UTRs, would be de-
sirable in this scenario. This issue was supported by
Marchuk, and the results of the Arup group can serve as
an alternative to looking for new HHT genes [26].
Van Sant-Webb and colleagues demonstrated that
some HHT patients with no known genetic cause may
have a deleterious non-coding region variant in a known
HHT gene [27].
One could imagine that including longer upstream re-
gions of the promoters (primarily ENG and ACVRL1/
ALK1) and sequencing the introns would increase the
feasibility to find variants affecting the splicing and regu-
lation of the candidate genes, and the rate of genetic
diagnosis would increase significantly. The importance
of sequencing the entire ENG and ACVRL1/ALK1 (even
SMAD4 or BMP9) genes, depending on the clinical
symptoms, is clear before looking for additional genes.
Thus, the results shown in the present paper consti-
tute an example of the last statement.
Although there have been 2 previous reports of 3 vari-
ants affecting the 5′UTR region of ENG of Endoglin,
two were pathogenic as a result of the generation of an
alternative transcription start codon that was out of
frame, without excluding transcription factor binding
[19]. This is the first work showing that a change in the
proximal promoter of Endoglin precludes Sp1 transcrip-
tion factor binding around the −58 bp position in the
minus strand. Sp1 was described as an essential factor
for Endoglin basal transcription [23], in the absence of
TATA box.
Altogether, this paper concludes that whole gene se-
quencing, not just coding regions, of ENG, ACVRL1/
ALK1, and depending on the phenotype, even of Smad4
and BMP9, may reveal that non-coding regions play a
larger role in HHT disease pathogenesis, which may help
to cover the full range of genetic diagnoses in clinically
diagnosed patients.
Conclusion
This manuscript constitutes the first work, to the best of
our knowledge, demonstrating a mutation in the prox-
imal promoter of Endoglin that affects the transcrip-
tional regulation of Endoglin, downregulating it and
leading to likely HHT pathogenic manifestations. The
change of a single nucleotide precludes the binding of
Sp1, which is an essential factor for Endoglin basal tran-
scription, around the −58 bp location in the minus
strand.
Many HHT patients with unknown genetic profiles
may have mutations located in the regulatory regions of
either Endoglin or ACVRL1/ALK1. This work empha-
sizes the need for increased coverage by sequencing of
non-coding regions in the relevant loci, uncovering re-
gions that have not been observed in exome sequencing.
It is very likely that in HHT we do not need to look
for more genes but should instead consider the entire
genomic sequence of ACVRL1/ACVRL1/ALK1 and ENG
to identify changes in non-coding regions that may affect
transcription, splicing and even translation.
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Fig. 5 Gel shift assay of nuclear extract from endothelial cells
showing a retarded band of protein-DNA, within the proximal pro-
moter of Endoglin. Nuclear extract from endothelial cells (HMEC-1
cell line) was incubated with the double stranded biotinylated oligo-
nucleotide, and in the presence of unspecific competitor (poli dI-
dC), a retarded band could be detected (lane 2). However, the sam-
ple was specifically treated with 100× excess of the unlabeled
double-stranded nucleotide (cold probe) (lane 3); when the mutated
oligonucleotide was added, the binding efficiency of the probe was
not diminished (lane 4). The experiment was repeated 4 times. This
image is representative of the obtained results
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